Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 16, 2011, Pages

  Conly, Jon ^a,b   Clement, Fiona ^c   Tonelli, Marcello ^a,b,d   Hemmelgarn, Brenda ^a,b,c   Klarenbach, Scott ^a,b,d   Lloyd, Anita ^a,b,d   McAlister, Finlay A ^d   Husereau, Don ^f   Wiebe, Natasha ^a,b,d   Au, Flora ^a,b   Manns, Braden ^c,e  

^a Alberta Kidney Disease Network   (Canada)

^b Alberta Kidney Disease Network   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG POTENCY; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW;

EID: 81055155570     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101281     Document Type: Article

References (30)

1. van Boven AJ, Brugemann J, de Graeff PA, et al. The 4S study. Implications for prescribing. Drugs 1996;51:507-14.
2. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160.
3. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
4. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010;170:1032-6.
5. Green LA. Cholesterol-lowering therapy for primary prevention: still much we don't know. Arch Intern Med 2010;170:1007-8.
6. Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med 2010;170:1073-7.
7. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010;170:1024-31.
8. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 reccommendations. Can J Cardiol 2009;25:567-79.
9. Canadian Institute for Health Information. Drug expenditure in Canada, 1985 to 2009. Ottawa (ON): The Institute; 2010.
10. Raymond CB, Morgan SG, Katz A, et al. A population-based analysis of statin utilization in British Columbia. Clin Ther 2007; 29:2107-19. (Pubitemid 350218117)
11. Nissen SE, Nicholls SJ, Sipahi L, et al. Effect of very high-intenisty statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial. JAMA 2006;295:1556-65.
12. Alberta Health and Wellness drug benefit list: pricing policy. Edmonton (AB): Alberta Health and Wellness; 2010.
13. Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a metaanalysis. CMAJ 2011;183:E1189-1202.
14. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada 3rd ed. Ottawa (ON): The Agency; 2006.
15. Berthiaume L. A cost-utility analysis of decompressive hemicraniectomy in pateints with malignant middle cerebral artery infarction. University of Calgary [thesis]; 2009.
16. Davies RA. Overview of 'APPROACH' - the Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease. Can J Cardiol 2000;16:1222-4.
17. Skrabal MZ, Stading JA, Cannella CA, et al. Two cases of rhabdomyolysis associated with high-dose simvastatin. Am J Health Syst Pharm 2003;60:578-81. (Pubitemid 36752888)
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
19. Kalra L, Evans A, Perez I, et al. Alternative strategies for stroke care: a prospective randomized controlled trial. Lancet 2000;356:894-9.
20. Deaths and mortality rates, by age group and sex, Canada, provinces and territories, annual. CANSIM Table 102-0504. Ottawa (ON): Statistics Canada; 2011.
21. Canadian community health survey (CCHS): annual component user guide. Ottawa (ON): Statistics Canada; 2009.
22. Muntner P, Mann D, Razzouk L, et al. Is measuring C-reactive protein useful for guiding treatment in women > or = 60 years and men > or = 50 years of age? Am J Cardiol 2009;104:354-8.
23. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-9. (Pubitemid 32710322)
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT- LLT). JAMA 2002;288:2998-3007.
25. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63. (Pubitemid 44444932)
26. Johannesson M, Jonsson M, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6. (Pubitemid 27057183)
27. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
28. Mihaylova B, Briggs A, Armitage J, et al.; Heart Protection Study Collaborative. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145.
29. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. The Institute; 2008. Available: www .nice.org.uk /media /C18/30/SVJ2PUBLICATION2008. pdf (accessed 2008 Nov. 10).
30. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009;150:243-54.